Societal CDMO, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-16: Form 8-K; Period of report 2016-12-16; Description 8.01 Other Events; Details 8.01.
- 2016-12-08: Form 8-K; Period of report 2016-12-08; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2016-11-30: Form 8-K; Period of report 2016-11-30; Description 8.01 Other Events; Details 8.01.
- 2016-11-28: Form 8-K; Period of report 2016-11-28; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-16 | 8-K | 2016-12-16 | 8.01 Other Events | 8.01 On December 16, 2016, Recro Pharma, Inc. (the “Company”) announced that it closed its underwritten public offering (the “Offering”) of 6,500,000 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). | d311477d8k.htm |
| 2016-12-08 | 8-K | 2016-12-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d255268d8k.htm |
| 2016-11-30 | 8-K | 2016-11-30 | 8.01 Other Events | 8.01 On November 30, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d289202d8k.htm |
| 2016-11-28 | 8-K | 2016-11-28 | 8.01 Other Events | 8.01 On November 28, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing positive results from its second of two Phase III clinical trials evaluating intravenous meloxicam for the treatment of acute postoperative pain (the “Phase III Results”). | d288858d8k.htm |
| 2016-11-15 | 8-K | 2016-11-15 | 8.01 Other Events | 8.01 On November 15, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d291312d8k.htm |
| 2016-11-10 | 8-K | 2016-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2016. | d291040d8k.htm |
| 2016-09-12 | 8-K | 2016-09-12 | 8.01 Other Events | 8.01 On September 12, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d257765d8k.htm |
| 2016-09-08 | 8-K | 2016-09-07 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 7, 2016, Recro Pharma, Inc. (the “Company”) announced that it will present a poster presentation entitled “An Evaluation of the Safety and Efficacy of N1539, a Novel Intravenous Formulation of NanoCrystalMeloxicam, Administered By IV Push in Subjects with Moderate to Severe Pain Following Bunionectomy” at the this year’s PAINWeek®, the National Conference on Pain for Frontline Practitioners, taking place in Las Vegas, NV from September 6 – 10, 2016. 8.01 On September 7, 2016, the Company issued a press release announcing the poster presentations at the PAINWeek® conference. | d251599d8k.htm |
| 2016-08-17 | 8-K | 2016-08-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d229221d8k.htm |
| 2016-08-12 | 8-K | 2016-08-11 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On August 11, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2016. 8.01 On August 12, 2016, the Company updated information reflected in a slide presentation, including certain financial information, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. | d239451d8k.htm |
| 2016-07-27 | 8-K | 2016-07-26 | 8.01 Other Events | 8.01 On July 26, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing positive top-line results from its pivotal phase III clinical trial of IV meloxicam (the “Phase III Results”). | d199979d8k.htm |
| 2016-07-14 | 8-K | 2016-07-14 | 8.01 Other Events | 8.01 On July 14, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d400569d8k.htm |
| 2016-07-05 | 8-K | 2016-07-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 5, 2016, Recro Pharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) has appointed Michael Celano as Chief Financial Officer of the Company, effective immediately. | d214507d8k.htm |
| 2016-05-25 | 8-K | 2016-05-24 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 On May 24, 2016, Recro Pharma, Inc. (the “Company”) held its 2016 Annual Meeting of Shareholders (the “Annual Meeting”). 8.01 On May 25, 2016, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d197758d8k.htm |
| 2016-05-12 | 8-K | 2016-05-12 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 12, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2016. 7.01 On May 12, 2016, Recro Pharma, Inc. presented a poster entitled “An Evaluation of the Efficacy and Safety of N1539, a Novel Intravenous Formulation of NanoCrystal Meloxicam, in Subjects with Moderate to Severe Pain Following Hysterectomy” at the 35th Annual Meeting of the American Pain Society in Austin, Texas. | d165122d8k.htm |
| 2016-04-29 | 8-K/A | 2015-04-10 | 9.01 Financial Statements and Exhibits | 9.01 (b) Pro Forma Financial Information. | d190006d8ka.htm |
| 2016-03-24 | 8-K | 2016-03-24 | 2.02 Results of Operations and Financial Condition | 2.02 On March 24, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2015. | d167278d8k.htm |
| 2016-03-14 | 8-K | 2016-03-14 | 8.01 Other Events | 8.01 On March 14, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d161544d8k.htm |
| 2016-02-22 | 8-K | 2016-02-17 | 2.02 Results of Operations and Financial Condition | 2.02 On February 17, 2016, pursuant to the terms of Recro Pharma, Inc.’s (the “Company”) credit agreement with Orbimed Royalty Opportunities II, LP, the Company paid approximately $2.6 million, 50% of the free cash flow generated during the fourth quarter of 2015 by the Company’s subsidiary, Recro Gainesville, LLC, against the outstanding principal on its senior secured term loan. | d138712d8k.htm |
| 2016-02-16 | 8-K | 2016-02-16 | 8.01 Other Events | 8.01 On February 16, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing the appointment of Fred Graff, as Chief Commercial Officer of the Company. | d129750d8k.htm |
| 2016-02-12 | 8-K | 2016-02-11 | 8.01 Other Events | 8.01 Recro Pharma, Inc. (the “Company”) has provided the following information for the purpose of providing additional supplemental information to supplement the disclosure contained in the Company’s Post-Effective Amendment No. 1 to Form S-1 (No. 333-201841), filed with the Securities and Exchange Commission (“SEC”) on December 23, 2015, and declared effective on January 11, 2016, and the Company’s Registration Statement on Form S-3 (No. 333-201841), filed with the SEC on August 28, 2015, as amended, and declared effective on September 1, 2015. | d142543d8k.htm |
| 2016-02-01 | 8-K | 2016-02-01 | 8.01 Other Events | 8.01 On February 1, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing that the first patient was dosed in the pivotal Phase III clinical trial evaluating intravenous meloxicam (N1539) for acute postoperative pain in patients following bunionectomy surgery. | d129124d8k.htm |
| 2016-01-27 | 8-K | 2016-01-27 | 8.01 Other Events | 8.01 On January 27, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing the initiation of its pivotal Phase III clinical trial of IV Meloxicam for acute postoperative pain in patients following abdominoplasty surgery. | d101344d8k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 8.01 Other Events | 8.01 On January 11, 2016, Recro Pharma, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d116570d8k.htm |
| 2016-01-06 | 8-K | 2016-01-06 | 8.01 Other Events | 8.01 On January 6, 2016, Recro Pharma, Inc. (the “Company”) issued a press release announcing positive results from its Phase II clinical trial evaluating intravenous (IV) meloxicam for the treatment of acute pain following bunionectomy surgery. | d108338d8k.htm |